Abera Bioscience (ABERA) investor relations material

Executive summary

• Completed GMP production of lead pneumococcal vaccine candidate Ab-01.12 and submitted regulatory application for first clinical trial in the Netherlands, marking transition to clinical development.

• Achieved promising preclinical results for intranasal influenza vaccine candidate, with successful ferret studies and ongoing CEPI funding.

• Published scientific articles in npj Vaccines and Vaccine, enhancing credibility and visibility of technology.

• Raised approximately 7.9 MSEK through exercise of warrants, reflecting strong shareholder confidence.

Financial highlights

• Net sales for Q2 2026 were 0 KSEK; other operating income was 1,563 KSEK, mainly from grants.

• Operating loss for Q2 2026 was -5,627 KSEK, compared to -842 KSEK in Q2 2025.

• Net loss after financial items for Q2 2026 was -5,559 KSEK, versus -833 KSEK in Q2 2025.

• Cash and cash equivalents at June 30, 2026, were 17,709 KSEK, up from 7,948 KSEK a year earlier.

• Equity at June 30, 2026, was 17,925 KSEK, up from 7,768 KSEK at June 30, 2025.

Outlook and guidance

• Awaiting regulatory feedback to initiate first-in-human clinical trial for Ab-01.12 in the Netherlands.

• Preparing for industrial production and toxicology studies for influenza vaccine candidate, supported by extended CEPI funding.

• Focus remains on advancing pipeline and publishing further scientific results.